NCT05205005View on ClinicalTrials.gov

Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

March 31, 2024

Study Completion Date

July 31, 2024

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Endocalyx

3,712mg (six capsules) of DSGP for eight weeks.

DRUG

Placebo

Ingredients per capsule (6 capsules per day) Nu-Mag Nat 10.00mg Rice Flour White 830 mg Magnesium Stearate 10.00mg

Trial Locations (1)

65201-5275

Harry S. Truman Memorial, Columbia, MO, Columbia

All Listed Sponsors
lead

VA Office of Research and Development

FED